Roche
NEWS
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
Christina Smolke said the financing will enable the company to use its synthetic biology platform to support essential medications that rely on plant-based materials.
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
The company said it will file a marketing application later this year for the drug under the FDA’s accelerated approval pathway.
Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.
Three other drug contenders that work similarly to Biogen’s drug are currently in clinical trials and expecting data relatively soon.
The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.
The clinical trial, which will be conducted by Xilio, will assess XTX101’s safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.
JOBS
IN THE PRESS
